Background and Purpose-Acute ischemic strokes under vitamin K antagonist (VKA) treatment are not uncommon, but intravenous thrombolysis (IVT) is not recommended for international normalized ratio (INR) >1.7 because of the excess bleeding risk. However, VKA-induced anticoagulation can be easily reversed by IV infusions of 4-factor prothrombin complex concentrate bolus and vitamin K. Our pilot study aimed to determine whether IVT immediately after anticoagulation reversal could be feasible and safe in acute ischemic stroke patients under VKA with INR >1.7. Methods-Consecutive acute ischemic stroke patients, otherwise eligible for IVT except for VKA intake and INR >1.7, were given IVT after infusing 4-factor prothrombin complex concentrate and vitamin K. Safety and efficacy were assessed clinically and by cerebral imaging at 24 hours. Results-Twenty-six patients (age, 77.8±12.8 years; atrial fibrillation, 84.6%; initial National Institutes of Health Stroke Scale, 11.6±5.6) were prospectively included. INR values were 2.3±0.6 initially and 1.3±0.2, 5 minutes postreversal. No symptomatic intracranial hemorrhage or thrombotic events occurred during the first 3 days. One patient developed major systemic hemorrhoidal bleeding that required blood transfusion; 61.5% of the patients were independent (modified Rankin Scale score of ≤2) at 3 months. Conclusions-A reversal strategy of 4-factor prothrombin complex concentrate bolus and vitamin K before IVT could be feasible and safe in acute ischemic stroke patients under VKA with INR >1.7. Well-designed, randomized controlled trials are warranted to confirm these preliminary findings.
V itamin K antagonists (VKAs) are still used to prevent ischemic stroke (IS) in patients with atrial fibrillation and remain the only recommended oral treatment for patients with mechanical heart valves. However, the annual acute IS (AIS) risk is as high as ≈1.7% for VKA-treated atrial fibrillation patients, occurring despite 30% of them having an international normalized ratio (INR) ≥2.
1 Intravenous thrombolysis (IVT) is not recommended for patients with INR >1.7. 2 Although never clearly evaluated in humans, animal study results confirmed an excess bleeding risk after IVT with an elevated INR. 3 Pertinently, VKA-induced anticoagulation can be rapidly reversed by IV infusions of 4-factor prothrombin complex concentrate (4F-PCC) and vitamin K. In a thromboembolic model of VKA-pretreated rodents, PCC prevented secondary hemorrhage post-IVT. 3 Only a few similar human cases given PCC have been reported. 4 This study was undertaken to determine whether IVT immediately after a 3-minute infusion of 4F-PCC and vitamin K could be feasible and safe in VKA-treated AIS patients with INR >1.7.
Methods
This prospective study (August 2012 to February 2015), conducted in our stroke unit, included consecutive AIS patients who were otherwise eligible for IVT, except for VKA intake and INR >1.7. The 4F-PCC (Kanokad, LFB, France) dose was calculated according to the INR value (see https://www.ahajournals.org/journal/str). Given the short 4F-PCC half-life (≈6 hours), IV vitamin K administration (10 mg over 1 hour) was systematically added. IVT was then immediately initiated, without waiting for the postreversal INR result. 5 INR was determined before IVT, then at 5 minutes, 4 to 6 hours, and 24 hours post-VKA reversal. When INR >1.7 persisted during monitoring, additional 4F-PCC and vitamin-K doses were given.
The clinical outcome was evaluated with the National Institutes of Health Stroke Scale (NIHSS) before IVT, at 24 hours, and at discharge and the modified Rankin Scale score at 3 months. Safety was assessed clinically, looking for systemic thrombosis (dyspnea, chest, or lower limb pain) or any bleeding, and with 24-hour magnetic resonance imaging (or computed tomographic angiography), ECG, and hemoglobin levels. For patients with intracranial arterial occlusions, recanalization at 24 hours was defined as Thrombolysis in Myocardial Infarction grade 3/2b. Symptomatic intracerebral hemorrhage (sICH) was defined as parenchymal hematoma type-2 or remote parenchymal hematoma type-2 on imaging within 36 hours from stroke onset combined with neurological deterioration of ≥4 NIHSS points. The primary end point was procedure safety, assessed over 72 hours, mortality, sICH, or major systemic bleeding (>2 g/dL hemoglobin decline), and thrombotic events, new cerebral, myocardial or lung infarction, or deep venous thrombosis. On the basis of a 20-patient sample, no >2 cases of IVT-related sICH or major systemic bleeding and no >2 cases with thrombotic events would be expected. Planned recruitment would stop if >2 patients developed sICH/major systemic bleeding or >2 patients developed thrombotic events. For IVT-related sICH, standard treatment guidelines were applied. 7 Secondary end points were early neurological course (24-hour NIHSS), arterial recanalization (Thrombolysis in Myocardial Infarction 3/2b) at 24 hours, and 3-month modified Rankin Scale score functional outcome. Results are expressed as mean±SD or number (%). The data supporting this study findings are available from the corresponding author on request.
Ethics
Written consent was provided by patients or next of kin. The local Ethics Committee and our prospective database (Commission Nationale d'Informatics et des Libertés 1927817v0) approved this study.
Results
Twenty-six consecutive AIS patients (77.8±12.8 years) underwent VKA reversal before IVT (Table I in the online-only Data Supplement); none of them had additional mechanical thrombectomy. Their baseline characteristics and outcome measures are given in Tables 1 and  2 . Most were receiving anticoagulation for atrial fibrillation (84.6%). Initial NIHSS was 11.6±5.6 and ≥10 for 15 of 26 (57.7%) patients. Magnetic resonance imaging was obtained for 23 of 26 (88.5%) patients, computed tomographic angiographies for the others ( Figure I in the onlineonly Data Supplement).
The emergency INR of 2.3±0.6 decreased to 1.3±0.2, 5 minutes postreversal. Subsequently, one patient's INR rose to 2.1 at 4 to 6 hours, attributed to post-thrombolytic coagulopathy; he did not receive the protocol-required additional 4-PCC or vitamin K dose.
Nine (34.6%) patients had minor ICHs at 24 hours, none of which were symptomatic ( Table 2 ). The post-thrombolytic coagulopathy patient experienced massive hemorrhoidal bleeding on day 2 requiring blood transfusion.
No thrombotic event occurred during 72 hours. Two atrial fibrillation patients experienced subsequent AISs on days 4 and 15 post-IVT, before restarting anticoagulation. At 3 months, 3 patients, 83, 88, and 89 years old, had died of the following causes: failed recanalization of a tandem occlusion, severe AIS recurrence on day 15, and fatal aspiration pneumonia on day 7. Intracranial arterial occlusions were found in 21 of 26 patients. NIHSS fell from 11.6±5.6 initially to 3.9±6.2 at discharge (Table 2): 73.1% had improved dramatically (≥4 points or final NIHSS score of 0) at 24 hours. In patients with distal occlusions (M2/3/4), initial and 24-hour NIHSSs were 8.1±4.5 and 0.3±0.7, respectively; 71.4% of the 21 patients with visible arterial occlusions were recanalized at 24 hours; 61.5% of the patients had 3-month modified Rankin Scale score of ≤2. 
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Discussion
AISs in VKA-treated patients are thought to be mostly minor, clearly different from our unselected patients. Our nonrandomized pilot study evaluating a VKA anticoagulation reversal strategy with bolus 4F-PCC and vitamin K before IVT showed only 1 of 26 major systemic hemorrhage and no sICHs. Moreover, no observations were suggestive of an increased bleeding risk for asymptomatic hemorrhage, with an overall 34.6% (9/26) cerebral hemorrhage rate, similar to those of other studies based on 24-hour gradient-echo T2* magnetic resonance imaging control (range, 39.5%-48.4%). 8 No excess thrombotic risk was seen during the first 72 hours, although 2 of 26 (7.7%) patients had recurrent AISs before restarting anticoagulation, in agreement with the 5% to 8% recurrence rate over 14 days without anticoagulation. 9 Indeed, the thrombotic complication rate post-VKA reversal with 4F-PCC for bleeding was 2.5% at 30 days in a large recent meta-analysis. 10 For VKA-treated patients with INR >1.7 and AISs because of proximal occlusion, mechanical thrombectomy seems to be safe. 11 However, in geographic regions without that technique or when arterial occlusions are distal or invisible, our reversal strategy could be considered. Interestingly, a similar pre-IVT, anticoagulation reversal strategy recently obtained promising results in dabigatran-treated patients using its specific antidote idarucizumab, 12 which has a 4.8% estimated thrombotic complication rate within 30 days. 13 To conclude, VKA-treated AIS patients with INR >1.7 could benefit from IVT after anticoagulation reversal. However, given the small sample included and the lack of a comparison group, our results require confirmation by further well-designed, randomized controlled trials.
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